Megestrol acetate: clinical experience.
Schacter
L
L
Pharmaceutical Research and Development Division, Bristol-Myers Co., Wallingford, CT 06492.
Rozencweig
M
M
Canetta
R
R
Kelley
S
S
Nicaise
C
C
Smaldone
L
L
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D000818:Animals; D000855:Anorexia / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D002100:Cachexia / Q000188:drug therapy / Q000209:etiology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D003272:Contraceptive Agents, Male / Q000008:administration & dosage; D003276:Contraceptives, Oral / Q000008:administration & dosage; D004714:Endometrial Hyperplasia / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011817:Rabbits; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy
D003272:Contraceptive Agents, Male; D003276:Contraceptives, Oral; D013629:Tamoxifen; D008535:Megestrol; D019290:Megestrol Acetate